Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture

Virchows Archiv

Volumn 444, Issue 2, 2004, Pages 175-182

  Barbosa, Edson Mantovani ^a   Nonogaki, Sueli ^b   Katayama, Maria Lucia Hirata ^c   Folgueira, Maria Aparecida Azevedo Koike ^c   Alves, Venâncio Ferreira Avancini ^b   Brentani, Maria Mitzi ^c  

^a Instituto Brasileiro de Controle do Cancer   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast cancer; Calcitriol; Fibroblasts; Organ culture; PAI 1

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; COLECALCIFEROL RECEPTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER; UROKINASE; UROKINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER TISSUE; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STROMA CELL; TISSUE CULTURE; TUMOR CELL;

BLOTTING, NORTHERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CELL LINE, TUMOR; CHOLECALCIFEROL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ORGAN CULTURE TECHNIQUES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CALCITRIOL; RECEPTORS, CELL SURFACE; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR;

EID: 1542375157     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-003-0929-5     Document Type: Article

References (46)

1. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Dano K (1986) Plasminogen activator inhibitor type-I: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 209:213-218
2. Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1-22
3. Arnheim N (1979) Characterization of mouse ribosomal gene fragments purified by molecular cloning. Gene 7:83-96
4. Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 14:923-928
5. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD, Hsieh JT (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Urol Oncol 21:314-315
6. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51:239-244
7. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60:597-603
8. Christensen L, Simonsen ACW, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA (1996) Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66:441-452
9. Clemens TL, Garrett KP, Zhou X-Y, Pike JW, Haussler MR, Dempster DW (1988) Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology 122:1224-1230
10. Colston KW, Hansen CM (2002) Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9:45-59
11. Constantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77:1079-1088
12. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563-1571
13. Dublin E, Hanby A, Patel NK, Liebman R, Barnes D (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am J Pathol 157:1219-1227
14. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R (2000) The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 60:4412-4418
15. Escaleira MTF, Brentani MM (1999) Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res Treat 54:123-133
16. Faraco JH, Morrison NA, Baker A, Shine J, Frossard PM (1989) ApaI dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res 17:2150
17. Friedrich M, Rafi L, Tilgen W, Schmidt W, Reichrath J. Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma (1998) J Histochem Cytochem 46:1335-1337
18. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W (2002) Analysis of vitamin D-receptor (VDR) and retinoic X-receptor α in breast cancer. Histochem J 34:35-40
19. Friedrich M, Villena-Heinsen C, Tilgen W, Schmitd W, Reichrath J, Axt-Fliedner R (2002) Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res 22:1919-1924
20. Fukumoto S, Allan EH, Martin TJ (1994) Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. Biochem Biophys Acta 1201:223-228
21. González-Sancho JM, Alvarez-Dolado M, Muñoz A (1998) 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expresión in mammary epithelial cells. FEBS Lett 426:225-228
22. Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035-2040
23. Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M (1991) Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 110:27-32
24. Jankun J, Merrick HW, Goldblatt PJ (1993) Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53:135-144
25. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J (2001) Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15:1370-1380
26. Jing Y, Xu XC, Lotan R, Waxman S, Mira-y-Lopes R (1996) Human breast carcinoma slice cultures retain retinoic acid sensitivity. Braz J Med Biol Res 29:1105-1108
27. Katayama MLH, Pasini FS, Folgueira MAAK, Snitcovsky IML, Brentani MM (2003) Molecular targets of 1,25(OH)2D3 in Hc11 normal mouse mammary cell line. J Steroid Biochem Mol Biol 84:57-69
28. Kennedy S, Duffy MJ, Duggan C, Bernes C, Rafferty R, Kramer MD (1998) Semi-quantification of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Brit J Cancer 77:1638-1641
29. Kole KL, Gyetko MR, Simpson RU, Sitrin RG (1991) Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. Biochem Pharmacol 41:585-591
30. Koli K, Keski-Oja J (1993) Vitamin D3 and calcipotriol decrease extra cellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 101:706-712
31. Koli K, Keski-Oja J (1996) Vitamin D3 regulation of transforming growth factor-beta system in epithelial and fibroblast cells relationships to plasminogen activation. J Invest Dermatol Symp Proc 1:33-38
32. Koli K, Keski-Oja J (2000) 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion associated proteases in cultured malignant cells. Cell Growth Differ 11:221-229
33. Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, Kang S, Fisher J, Voorhees JJ (1999) 1,25-dihydroxyvitamin D3 increases nuclear vitamin D3 receptor by blocking ubiquitin/proteasome mediated degradation in human skin. Mol Endocrinol 13:1986-1994
34. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Fred Sweep CGJ, Ulm K, Peyrat J-P, Martin P-M, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl P-O, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder E, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbihler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LVAM, Klijn JGM, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Nat Cancer Inst 94:116-128
35. Mira-y-Lopes R, Osborne MP, Depalo AJ, Ossowski L (1991) Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. Int J Cancer 47:827-832
36. Mondino A, Resnati M, Blasi F (1999) Structure and function of the urokinase receptor. Thromb Haemost 82:19-22
37. Mork-Hansen C, Frandsen TL, Brunner N, Binderup L (1994) 1α,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12:195-202
38. Narvaez CJ, Zinser G, Welsh J (2001) Functions of 1alpha,25- dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 66:301-308
39. Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K (1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74:168-177
40. Ree AH, Pacheco MM; Tvermyr M, Fodstad O, Brentani MM (2000) Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res 6:1778-1783
41. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727-732
42. Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22:205-222
43. Sieuwerts AM, Martens JW, Dorssers LC, Klijn JG, Foekens JA (2002) Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts. Thromb Haemost 87:674-683
44. Stamps AC, Davies SC, Burman J, O'Hare MJ (1994) Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 57:865-874
45. Uemeda T, Eguchi Y, Okino K, Kodama M, Hattori T (1997) Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183:388-397
46. Yudoh K, Matsui H, Tsuji H (1997) Effects of 1,25-dihydroxy-vitamin D3 on tumor cell invasion to the extracellular matrix in human fibrosarcoma HT1080 cells and its correlation with laminin. Tumor Biol 18:69-79